A new article on Finance Registrar focuses on MJNA’s market cap and spotlights recent developments of its subsidiaries.
Medical Marijuana, Inc. and its subsidiary HempMeds® Brasil received high praise recently in an online article by Finance Registrar. The finance industry and investing news site spotlighted MJNA’s market cap, which it reported has surged from $180M to $343.4M.
In the piece, contributor Ross McDonald highlighted HempMeds® Brasil, whose CBD oil products were the first cannabis-based products legally authorized for import by ANVISA for patients in Brazil. Patients in Brazil can gain access to HempMeds® Brasil’s Real Scientific Hemp Oil™ (RSHO™) pure CBD hemp oil after gaining their doctor’s prescription and authorization from ANVISA to import the products.
Referring to RSHO™ as the “go-to” cannabinoid in Brazil, McDonald detailed the publicity the company received after a young girl there used the CBD oil.
McDonald also briefly highlighted MJNA subsidiary Kannaway™, a network sales and marketing company in the hemp space that has experienced 18 consecutive months of growth. He also noted the research and development of cannabinoid-based pharmaceuticals by MJNA investment companies and shared the results of a recent clinical study MJNA participated in.
MJNA a “Trailblazer”
In conclusion, the Finance Registrar piece touted that “CBD oils may end up being one of the most lucrative parts of the cannabis boom” and spotlighted Medical Marijuana, Inc. as a “trailblazer” and “truly a company to watch.”
Read the full Finance Registrar article HERE.
Discover more from HempMeds® Brasil and the Medical Marijuana, Inc. portfolio of companies on our news feed.
